International Journal of Alzheimer’s Disease

International Journal of Alzheimer’s Disease / 2013 / Article

Research Article | Open Access

Volume 2013 |Article ID 108021 |

Markus Donix, Maria Scharf, Kira Marschner, Annett Werner, Cathrin Sauer, Antje Gerner, Josef A. Nees, Shirin Meyer, Katharina L. Donix, Rüdiger Von Kummer, Vjera A. Holthoff, "Cardiovascular Risk and Hippocampal Thickness in Alzheimer’s Disease", International Journal of Alzheimer’s Disease, vol. 2013, Article ID 108021, 7 pages, 2013.

Cardiovascular Risk and Hippocampal Thickness in Alzheimer’s Disease

Academic Editor: Kurt A. Jellinger
Received15 Jun 2013
Accepted10 Sep 2013
Published21 Oct 2013


Cardiovascular risk factors influence onset and progression of Alzheimer’s disease. Among cognitively healthy people, changes in brain structure and function associated with high blood pressure, diabetes, or other vascular risks suggest differential regional susceptibility to neuronal damage. In patients with Alzheimer’s disease, hippocampal and medial temporal lobe atrophy indicate early neuronal loss preferentially in key areas for learning and memory. We wanted to investigate whether this regional cortical thinning would be modulated by cardiovascular risk factors. We utilized high-resolution magnetic resonance imaging and a cortical unfolding technique to determine the cortical thickness of medial temporal subregions in 30 patients with Alzheimer’s disease. Cardiovascular risk was assessed using a sex-specific multivariable risk score. Greater cardiovascular risk was associated with cortical thinning in the hippocampus CA2/3/dentate gyrus area but not other hippocampal and medial temporal subregions. APOE genotype, a family history of Alzheimer’s disease, and age did not influence cortical thickness. Alzheimer’s disease-related atrophy could mask the influence of genetic risk factors or age on regional cortical thickness in medial temporal lobe regions, whereas the impact of vascular risk factors remains detectable. This highlights the importance of cardiovascular disease prevention and treatment in patients with Alzheimer’s disease.

1. Introduction

Patients with cardiovascular risk factors show an increased probability of developing cognitive decline and dementia [1, 2]. High blood pressure, diabetes, elevated cholesterol, and other vascular risks contribute to pathology resulting in cerebrovascular disease. However, studies have also demonstrated an association of these factors with Alzheimer’s disease [3, 4]. Alzheimer’s disease’s neuropathological hallmarks, beta-amyloid plaques and neurofibrillary tangles, and vascular pathology frequently cooccur in demented patients. It is not yet obvious whether and how pathological changes associated with vascular risks are closely related to Alzheimer’s disease etiology or whether they mainly mediate additional neuronal impairment ultimately contributing to the neurodegenerative disease’s onset or clinical course. There is faster cognitive deterioration in Alzheimer’s disease patients presenting with vascular risk factors [5], and, in contrast, treatment of such risks could slow this decline [6].

Damage of the blood-brain barrier with increased vascular permeability or high oxidative stress may be involved in both vascular dementia and Alzheimer’s disease [7]. Therefore vascular disease could stimulate the development of Alzheimer’s disease and vice versa [7]. Postmortem data show greater amyloid plaque burden in the hippocampus and in the neocortex of people that suffered from elevated systolic blood pressure [8]. Beta-amyloid peptide production could be increased in people with high blood pressure due to its vasoconstrictive properties [9]. Animal model data suggest a causal relationship between beta-amyloid plaque accumulation and hypertension, possibly through dysregulation of beta-amyloid trafficking [10]. Diabetes may contribute to cognitive decline and dementia via cerebrovascular changes such as atherosclerosis. However, insulin-degrading enzyme in the brain also regulates extracellular beta-amyloid levels [11]. Midlife cholesterol levels influence the development of Alzheimer’s disease later in life, also possibly involving mechanisms other than the vascular pathway [12].

Cardiovascular risk contributes to regional brain structure changes in aging in the absence of cerebrovascular disease [13], which can be detected in vivo using magnetic resonance imaging (MRI). These data also suggest a higher vulnerability of specific brain regions when compared with others. Among patients with Alzheimer’s disease, the earliest neuropathological changes can be found in the transentorhinal area before spreading to the hippocampus and subsequently to other brain regions [14]. Genetic risks, such as carrying the APOE-4 allele, contribute to brain structure changes [15] that may render people at higher risk of developing Alzheimer’s disease. However, composite factors, for example, a positive family history of Alzheimer’s disease, specifically acknowledge the possible influence of modifiable risk factors [16]. Raz and colleagues [17] demonstrated an accelerated age-related atrophy in the hippocampus but not in other brain regions among patients with high blood pressure, but it remains controversial whether or not hippocampal atrophy in aging is modulated by vascular risk [18].

The hippocampus is a heterogeneous area with subregions that might be differentially susceptible to the deleterious effects of vascular risk factors and resulting perfusion impairment [19, 20]. In this study we used high-resolution MRI and cortical unfolding image analysis [21] to investigate the relationship between subregional hippocampal thickness and cardiovascular risk factors in patients with Alzheimer’s disease. We hypothesized that increased cardiovascular risk would be associated with cortical thinning in the hippocampus CA2/3/dentate gyrus area. In contrast to other hippocampal subfields, this region is affected by neuronal damage at later neuropathological stages of the disease [14], possibly allowing for in vivo detection of the subtle modulating effect of vascular risks on neuronal structure.

2. Methods

2.1. Participants

We recruited 30 patients with Alzheimer’s disease (mean age 71.4 years ± 4.9 years, Table 1) through our university hospital’s memory clinic. These patients participate in cross-sectional and longitudinal investigations of biological and clinical parameters. Written informed consent was obtained and the university’s ethics committee approved the study. We only recruited Alzheimer’s disease patients who had the cognitive capacity for consent. This was established in a clinical evaluation by an independent psychiatrist. Alzheimer’s disease patients met standard clinical criteria [22]. All patients underwent APOE genotyping, MRI scanning, and extensive neuropsychological assessments. The patients did not have a history of cerebrovascular disease, psychiatric or neurological disorders other than Alzheimer’s disease, or any systemic disease possibly affecting brain function. Structural MRI evaluation and laboratory testing complemented the diagnostic procedures. We had 11 patients homozygous for the APOE-3 genotype in our sample and 19 patients carrying the APOE-4 risk allele including five homozygous carriers. There were no patients with the APOE-2/4 variant. All patients were right handed, on stable (>6 months) antidementive, for example, acetylcholinesterase inhibitor medication, and did not receive any other psychotropic medication. Investigators performing MRI scanning and cortical unfolding procedures were blinded for the patients’ clinical and demographic information.

Characteristic (range), mean ± SDAlzheimer’s disease patients

Age (years)
Female sex (no.)15
APOE-4 carriers (no.)19
Positive family history (no.)12
Minimental state examination (0–30)
Alzheimer’s disease assessment Scale-cognitive subscale (ADAS-Cog)
  Word recall (0–10)
  Word recognition (0–12)
  Remembering test instructions (0–5)
  Orientation (0–8)
  Commands (0–5)
  Spoken language (0–5)
  Naming objects and fingers (0–5)
  Word finding (0–5)
  Comprehension (0–5)
  Constructional praxis (0–5)
  Ideational praxis (0–5)
Trailmaking test
 Part A (sec.)
 Part B (sec.)

2.2. Vascular Risk Assessment

For the assessment of cardiovascular risk we used a sex-specific multivariable risk score [23]. This score is composed of several items (age, total and high-density lipoprotein cholesterol, systolic blood pressure, treatment for hypertension, smoking, and diabetes status) and has been developed in the Framingham Heart Study as a convenient tool to assess and to quantify cardiovascular risk and to guide preventive care [23].

2.3. MRI Scanning and Cortical Unfolding

Using a GE Signa HDxt 3-Tesla scanner (General Electric Health Care, Waukesha, Wisconsin) we obtained high-resolution oblique coronal T2-weighted fast-spin echo scans (repetition time: 5,200 msec; echo time: 105 msec; slice thickness: 3 mm; spacing: 0 mm; 19 slices; in-plane voxel size: 0.39 × 0.39 mm; field of view: 200 mm). Subsequent cortical unfolding procedures [21] result in a two-dimensional representation of the medial temporal lobe’s gray matter, substantially improving the visibility of the convoluted medial temporal lobe cortex (Figure 1). Briefly, after manually masking white matter and CSF, gray matter is grown out in connected layers using a region-expansion algorithm. Because we maximized in-plane resolution, MRI data were interpolated by a factor of seven, in order to achieve an approximately isotropic voxel size. The gray-matter volume containing cornu ammonis fields 1 (CA1), CA2, 3, and the dentate gyrus (CA23DG), the subiculum (SUB), entorhinal (ERC), perirhinal (PRC), and parahippocampal cortices (PHC), and the fusiform gyrus (FUS) is then computationally unfolded based on metric multidimensional scaling algorithms. Boundaries between subregions are delineated on the original MRI sequence using histological and MRI atlases [24, 25] and mathematically projected to their flat map space coordinates.

Consistent with our previous studies utilizing cortical unfolding, we report raw thickness data, which is also in line with different image analysis strategies that should be applied to cortical thickness measurements in contrast to volumetric data [26]. After confirming the normality of value distribution with the Kolmogorov-Smirnov test, we first estimated a multivariate general linear model, with APOE genotype and family history as between-group factors and cardiovascular risk score, MMSE score, and age as covariates. We used subregions as a within-group factor and conducted post hoc univariate tests across individual areas only after we established significance with the multivariate tests in order to minimize spurious findings within the regions we can separate in our image analysis. Post hoc linear regression analyses were conducted to determine the influence of vascular risk and MMSE performance on regional cortical thickness.

3. Results

For patient demographic and cognitive characterization, see Table 1. Utilizing a sex-specific multivariable risk score [23], our patients scored on average 15.3 points (SD 3.1, range 7–22). A high global risk (10-year risk >20%) of coronary, cerebrovascular, and peripheral arterial disease and heart failure [23] would be reflected in a score >17 points for women and >14 points for men. There were 15 patients with this high-risk profile among study participants. In our primary hippocampal region of interest (CA23DG), average cortical thickness across all patients was 2.78 millimeter (SD 0.14, range 2.52–3.04) in CA23DG. The multivariate general linear model revealed significant main effects for cardiovascular risk ( , df = 7,14, ) and MMSE score ( , df = 7,14, ) but not for APOE genotype, family history of Alzheimer’s disease, and age. Linear regression showed that greater cardiovascular risk was associated with cortical thinning in the CA23DG region ( = −0.5, , Figure 2) but not in CA1 or other medial temporal lobe subregions. Lower MMSE performance was associated with reduced cortical thickness in several subregions: ERC: = 0.4, , PRC: = 0.74, , PHC: = 0.6, , FUS: = 0.58, , and across all regions combined: = 0.59, . We did not detect hemispheric differences in the observed effects.

4. Discussion

We show an association between elevated cardiovascular risk and hippocampal thinning in our patients with Alzheimer’s disease. This effect was restricted to the CA23DG region. APOE genotype, a first-degree family history of Alzheimer’s disease, and age did not influence regional medial temporal lobe cortical thickness in our sample. With respect to age, this is particularly important since age itself is a component in the cardiovascular risk score we utilized [23]. It is possible that age effects on cortical thickness in this brain region are no longer obvious due to the substantial influence of disease-related atrophy. This is in line with disease severity, as reflected by the MMSE score, being associated with cortical thinning across several medial temporal subregions.

Genetic risks, such as carrying the APOE-4 allele, contribute to cortical thinning in the entorhinal cortex and the subiculum in cognitively healthy people [15]. APOE-4-associated cortical thinning in the hippocampus CA1 field has been reported as well [16], whereas CA23DG cortical thickness was not modulated by APOE genotype [15, 16]. Among our patients with Alzheimer’s disease we did not detect APOE effects on cortical thickness; however, others have found regionally selective APOE-4 effects on the hippocampal region [27]. Other variables, as reflected in a family history of Alzheimer’s disease, influence hippocampal cortical thickness independently and through interaction with the APOE genotype [16]. Furthermore, APOE-4 allele dose modulates hippocampal volume in Alzheimer’s disease patients [28]. The individual pattern of risk factors and their interactions could therefore contribute to some variability in brain imaging studies. Subtle APOE-4-associated changes on cortical structure may also become less consistently detectable in patients with a neurodegenerative disease. It is in line with the hypothesis that APOE is more important for the development rather than for the progression of Alzheimer’s disease [29].

We cannot determine, using structural MRI, whether and how vascular risk factors themselves contribute to Alzheimer’s disease development. The impact of blood pressure and blood sugar concentration elevation on beta-amyloid metabolism has been demonstrated in vitro and in animal models, pointing to possible pathways other than microvascular disease, such as dysregulation of beta-amyloid trafficking [10, 11] and blood-brain barrier damage [7]. Cardiovascular risk factors increase the risk of Alzheimer’s disease [3, 4] and contribute to Alzheimer’s disease progression [30]. Encouraging data show that treatment of such factors can reduce the conversion to Alzheimer’s disease in patients with mild cognitive impairment [2]. Moreover, it was shown that the treatment of cardiovascular risk factors could slow cognitive decline in Alzheimer’s disease even in the absence of obvious cerebrovascular disease [6]. The authors describe a progressive gradient of cognitive decline according to how many vascular risk factors were treated (all, some, or none), which suggests a causal relationship [6]. The association between antihypertensive treatment and the prevention of dementia and cognitive decline is well established, whereas the influence of treating hyperlipidemia on dementia risk is yet inconclusive, and positive effects may only be seen in specific populations [31, 32]. Lifestyle changes known to strengthen cardiovascular health, from Mediterranean diet to physical exercise, substantially contribute to cognitive fitness, lowering the risk of developing dementia [33].

Regionally specific brain structure changes shape our understanding of how a neurodegenerative disease develops or progresses. These characteristics guide research strategies, clinical diagnostic procedures, and the search for meaningful noninvasive biological markers. High-resolution MRI and innovative image analysis techniques make it possible to detect such brain structure changes in vivo, complementing other research modalities. Our MRI data suggest that, in Alzheimer’s disease patients, CA23DG is more susceptible than other regions to vascular risk factor-associated changes. This would be in line with the neuropathological observation of the CA3 and dentate gyrus region being affected at later stages of Alzheimer’s disease [14]. The CA23DG region’s structural integrity could be relatively intact so that it would respond to the subtle modulating influence of vascular risks, whereas greater neuronal damage in other regions already exceeds this effect. In a postmortem study, Schwartz and colleagues [20] showed an increase in mean vessel density and variance in the hippocampus CA1 field of Alzheimer’s disease patients, reflecting CA1 vulnerability to metabolic stress [19]. The CA3 field showed only milder vascular changes [20]. This could again indicate that strategies aimed at preventing the deleterious effects of cardiovascular risk factors might be beneficial for a region that is not already affected by extensive and permanent vascular pathology.

Memory impairment is highly interrelated to hippocampal CA3 and dentate gyrus functioning through the region’s essential role in pattern separation processes [34]. The main afferent input to this region is ERC neurons [25]. Pattern separation performance as well as ERC-CA3/dentate gyrus connectivity is already affected in normal aging [35]. There will be additional network changes due to ERC pathology-associated CA3/dentate gyrus deafferentation in Alzheimer’s disease patients. It remains unknown how much vascular risk factors contribute to these network changes. Furthermore, Alzheimer’s disease patients show impaired neurogenesis in the dentate gyrus [36], and, among other factors, vascular changes are possibly involved [37].

This study has several limitations. We did not examine healthy controls or other patient populations, which should be done in the future. Therefore, we cannot determine whether or not the association between cardiovascular risk and CA23DG thickness could be observed in individuals other than patients with Alzheimer’s disease. Previous work suggests that cortical structure changes due to the presence of cardiovascular risk factors can be detected in various brain areas including the hippocampus among healthy people [13, 17]. Raz and colleagues [17] found age-associated hippocampal volume changes only among participants with a diagnosis of hypertension. This interaction could not be detected in adjacent brain regions, such as the entorhinal cortex, suggesting that areas within the medial temporal lobe show differential vulnerability to vascular risk factors. However, due to methodological differences, these data do not exclude the possibility that the risk factor-associated patterns of subregional hippocampal structure changes differ between Alzheimer’s disease patients and nondemented subjects. Furthermore we are measuring cortical thickness, which does not allow direct comparisons with other studies investigating volumetric brain changes in Alzheimer’s disease patients.

Age itself did not influence the association between cardiovascular risk and cortical thickness in our sample, but it is a contributing factor in the cardiovascular risk score we utilized [23]. Therefore a score value does not only indicate the presence of specific additional risk factors (such as hypertension or diabetes). Although we had a homogeneous distribution from low-risk to high-risk patients, we were not able to establish patient subgroups (e.g., subjects with no risk factors other than their age) due to sample size limitations. We also might not have enough power to detect cortical thickness changes associated with the APOE-4 allele. However, our previous investigations in healthy people differing in APOE genotype suggest that the absence of this effect is not mainly driven by sample size [15, 16]. Finally, it is important to underline that an association of elevated cardiovascular risk with cortical thinning in the hippocampus CA23DG region using in vivo MRI does not prove a causal relationship between these risk factors and Alzheimer’s disease etiology or the disease’s clinical course. Although the CA23DG region responds to the subtle influence of vascular risk factors and other regions do not, cortical thickness measures alone are not sufficient to show that the neuronal architecture in this region is more preserved until later stages of the disease [14]. CA fields 2,3, and the dentate gyrus are difficult to differentiate using in vivo MRI, which may influence comparability with postmortem data.

5. Conclusions

Our data suggest a differential influence of cardiovascular risk on cortical thickness in hippocampal subregions among patients with Alzheimer’s disease. Other well-known risk factors of the disease, such as APOE-4, a positive family history, and age, did not modulate hippocampal cortical thickness in these patients. This highlights the possible impact of modifiable risk factors in a brain region to be critically important for the clinical presentation of Alzheimer’s disease patients.

Conflict of Interests

Rüdiger Von Kummer reports personal compensation for serving on the Advisory Board of Lundbeck AC, serving as Cochair on the Steering Committee of the DIAS-3 and -4 trials, serving on the image adjudication committee for these trials and for GAMES-RP, consulting Synarc, and organizing the core laboratory for REVASCAT and SITS OPEN. He is Section Editor for Interventional Neuroradiology of the journal Neuroradiology. Vjera Holthoff reports personal compensation for serving on the Advisory Board of Eli Lilly and Novartis. She has received honoraria by MERZ, Pfizer, and Janssen-Cilag. She serves as Principle Investigator in a study conducted by SERVIER CL2-38093-012. Other authors report no financial relationships with commercial interests.

Authors’ Contribution

Markus Donix and Maria Scharf have contributed equally to the paper.


The authors would like to thank Susan Bookheimer, Alison Burggren, Nanthia Suthana, Arne Ekstrom, and James Kyle for support and assistance with cortical unfolding.


  1. P. B. Gorelick, A. Scuteri, S. E. Black et al., “Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the American Heart Association/American Stroke Association,” Stroke, vol. 42, no. 9, pp. 2672–2713, 2011. View at: Publisher Site | Google Scholar
  2. J. Li, Y. J. Wang, M. Zhang et al., “Vascular risk factors promote conversion from mild cognitive impairment to Alzheimer disease,” Neurology, vol. 76, no. 17, pp. 1485–1491, 2011. View at: Publisher Site | Google Scholar
  3. M. Kivipelto, E.-L. Helkala, M. P. Laakso et al., “Midlife vascular risk factors and Alzheimer's disease in later life: Longitudinal, population based study,” British Medical Journal, vol. 322, no. 7300, pp. 1447–1451, 2001. View at: Google Scholar
  4. J. A. Luchsinger, C. Reitz, L. S. Honig, M.-X. Tang, S. Shea, and R. Mayeux, “Aggregation of vascular risk factors and risk of incident Alzheimer disease,” Neurology, vol. 65, no. 4, pp. 545–551, 2005. View at: Publisher Site | Google Scholar
  5. E. P. Helzner, J. A. Luchsinger, N. Scarmeas et al., “Contribution of vascular risk factors to the progression in Alzheimer disease,” Archives of Neurology, vol. 66, no. 3, pp. 343–348, 2009. View at: Publisher Site | Google Scholar
  6. Y. Deschaintre, F. Richard, D. Leys, and F. Pasquier, “Treatment of vascular risk factors is associated with slower decline in Alzheimer disease,” Neurology, vol. 73, no. 9, pp. 674–680, 2009. View at: Publisher Site | Google Scholar
  7. I. Skoog, R. N. Kalaria, and M. M. B. Breteler, “Vascular factors and Alzheimer disease,” Alzheimer Disease and Associated Disorders, vol. 13, supplement 3, pp. S106–S114, 1999. View at: Google Scholar
  8. H. Petrovitch, L. R. White, G. Izmirilian et al., “Midlife blood pressure and neuritic plaques, neurofibrillary tangles, and brain weight at death: the HAAS,” Neurobiology of Aging, vol. 21, no. 1, pp. 57–62, 2000. View at: Publisher Site | Google Scholar
  9. F. Crawford, Z. Suo, C. Fang, and M. Mullan, “Characteristics of the in vitro vasoactivity of β-amyloid peptides,” Experimental Neurology, vol. 150, no. 1, pp. 159–168, 1998. View at: Publisher Site | Google Scholar
  10. C. Diaz-Ruiz, J. Wang, H. Ksiezak-Reding et al., “Role of hypertension in aggravating abeta neuropathology of ad type and tau-mediated motor impairment,” Cardiovascular Psychiatry and Neurology, vol. 2009, Article ID 107286, 9 pages, 2009. View at: Publisher Site | Google Scholar
  11. W. Q. Qiu, D. M. Walsh, Z. Ye et al., “Insulin-degrading enzyme regulates extracellular levels of amyloid β- protein by degradation,” The Journal of Biological Chemistry, vol. 273, no. 49, pp. 32730–32738, 1998. View at: Publisher Site | Google Scholar
  12. A. Solomon, M. Kivipelto, B. Wolozin, J. Zhou, and R. A. Whitmer, “Midlife serum cholesterol and increased risk of Alzheimer's and vascular dementia three decades later,” Dementia and Geriatric Cognitive Disorders, vol. 28, no. 1, pp. 75–80, 2009. View at: Publisher Site | Google Scholar
  13. E. C. Leritz, D. H. Salat, V. J. Williams et al., “Thickness of the human cerebral cortex is associated with metrics of cerebrovascular health in a normative sample of community dwelling older adults,” NeuroImage, vol. 54, no. 4, pp. 2659–2671, 2011. View at: Publisher Site | Google Scholar
  14. H. Braak, I. Alafuzoff, T. Arzberger, H. Kretzschmar, and K. Tredici, “Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry,” Acta Neuropathologica, vol. 112, no. 4, pp. 389–404, 2006. View at: Publisher Site | Google Scholar
  15. A. C. Burggren, M. M. Zeineh, A. D. Ekstrom et al., “Reduced cortical thickness in hippocampal subregions among cognitively normal apolipoprotein E e4 carriers,” NeuroImage, vol. 41, no. 4, pp. 1177–1183, 2008. View at: Publisher Site | Google Scholar
  16. M. Donix, A. C. Burggren, N. A. Suthana et al., “Family history of Alzheimer's disease and hippocampal structure in healthy people,” American Journal of Psychiatry, vol. 167, no. 11, pp. 1399–1406, 2010. View at: Publisher Site | Google Scholar
  17. N. Raz, U. Lindenberger, K. M. Rodrigue et al., “Regional brain changes in aging healthy adults: general trends, individual differences and modifiers,” Cerebral Cortex, vol. 15, no. 11, pp. 1676–1689, 2005. View at: Publisher Site | Google Scholar
  18. T. Gattringer, C. Enzinger, S. Ropele et al., “Vascular risk factors, white matter hyperintensities and hippocampal volume in normal elderly individuals,” Dementia and Geriatric Cognitive Disorders, vol. 33, no. 1, pp. 29–34, 2012. View at: Publisher Site | Google Scholar
  19. R. Schmidt-Kastner and T. F. Freund, “Selective vulnerability of the hippocampus in brain ischemia,” Neuroscience, vol. 40, no. 3, pp. 599–636, 1991. View at: Publisher Site | Google Scholar
  20. E. Schwartz, B. Wicinski, J. Schmeidler, V. Haroutunian, and P. R. Hof, “CardIovascular risk factors affect hippocampal microvasculature in early ad,” Translational Neuroscience, vol. 1, no. 4, pp. 292–299, 2010. View at: Publisher Site | Google Scholar
  21. M. M. Zeineh, S. A. Engel, P. M. Thompson, and S. Y. Bookheimer, “Dynamics of the hippocampus during encoding and retrieval of face-name pairs,” Science, vol. 299, no. 5606, pp. 577–580, 2003. View at: Publisher Site | Google Scholar
  22. G. McKhann, D. Drachman, and M. Folstein, “Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA work group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease,” Neurology, vol. 34, no. 7, pp. 939–944, 1984. View at: Google Scholar
  23. R. B. D'Agostino Sr., R. S. Vasan, M. J. Pencina et al., “General cardiovascular risk profile for use in primary care: the Framingham heart study,” Circulation, vol. 117, no. 6, pp. 743–753, 2008. View at: Publisher Site | Google Scholar
  24. D. G. Amaral and R. Insausti, “Hippocampal formation,” in The Human Nervous System, G. Praxinos, Ed., pp. 711–755, Academic Press, San Diego, Calif, USA, 1990. View at: Google Scholar
  25. H. M. Duvernoy, The Human Hippocampus: Functional Anatomy, Vascularization, and Serial Sections with MRI, Springer, Berlin, Germany, 1998.
  26. E. Westman, C. Aguilar, J. S. Muehlboeck et al., “Regional magnetic resonance imaging measures for multivariate analysis in Alzheimer's disease and mild cognitive impairment,” Brain Topography, vol. 26, no. 1, pp. 9–23, 2013. View at: Google Scholar
  27. S. G. Mueller, N. Schuff, S. Raptentsetsang, J. Elman, and M. W. Weiner, “Selective effect of Apo e4 on CA3 and dentate in normal aging and Alzheimer's disease using high resolution MRI at 4 T,” NeuroImage, vol. 42, no. 1, pp. 42–48, 2008. View at: Publisher Site | Google Scholar
  28. Y. Liu, T. Paajanen, E. Westman et al., “Effect of APOE ε4 allele on cortical thicknesses and volumes: the addNeuroMed study,” Journal of Alzheimer's Disease, vol. 21, no. 3, pp. 947–966, 2010. View at: Publisher Site | Google Scholar
  29. S. L. Tyas, J. C. Salazar, D. A. Snowdon et al., “Transitions to mild cognitive impairments, dementia, and death: findings from the Nun study,” American Journal of Epidemiology, vol. 165, no. 11, pp. 1231–1238, 2007. View at: Publisher Site | Google Scholar
  30. H. Sakurai, H. Hanyu, T. Sato et al., “Vascular risk factors and progression in Alzheimer's disease,” Geriatrics and Gerontology International, vol. 11, no. 2, pp. 211–214, 2011. View at: Publisher Site | Google Scholar
  31. J. J. Monsuez, A. Gesquiere-Dando, and S. Rivera, “Cardiovascular prevention of cognitive decline,” Cardiology Research and Practice, vol. 2011, Article ID 250970, 7 pages, 2011. View at: Publisher Site | Google Scholar
  32. F. Forette, M. Seux, J. A. Staessen et al., “The prevention of dementia with antihypertensive treatment: new evidence from the Systolic Hypertension in Europe (Syst-Eur) study,” Archives of Internal Medicine, vol. 162, no. 18, pp. 2046–2052, 2002. View at: Publisher Site | Google Scholar
  33. N. Scarmeas, J. A. Luchsinger, N. Schupf et al., “Physical activity, diet, and risk of Alzheimer disease,” Journal of the American Medical Association, vol. 302, no. 6, pp. 627–637, 2009. View at: Publisher Site | Google Scholar
  34. A. Bakker, C. B. Kirwan, M. Miller, and C. E. L. Stark, “Pattern separation in the human hippocampal CA3 and dentate gyrus,” Science, vol. 319, no. 5870, pp. 1640–1642, 2008. View at: Publisher Site | Google Scholar
  35. M. A. Yassa, S. M. Stark, A. Bakker, M. S. Albert, M. Gallagher, and C. E. L. Stark, “High-resolution structural and functional MRI of hippocampal CA3 and dentate gyrus in patients with amnestic Mild Cognitive Impairment,” NeuroImage, vol. 51, no. 3, pp. 1242–1252, 2010. View at: Publisher Site | Google Scholar
  36. L. Crews, A. Adame, C. Patrick et al., “Increased BMP6 levels in the brains of Alzheimer's disease patients and APP transgenic mice are accompanied by impaired neurogenesis,” The Journal of Neuroscience, vol. 30, no. 37, pp. 12252–12262, 2010. View at: Publisher Site | Google Scholar
  37. P. M. Pimentel-Coelho and S. Rivest, “The early contribution of cerebrovascular factors to the pathogenesis of Alzheimer's disease,” European Journal of Neuroscience, vol. 35, no. 12, pp. 1917–1937, 2012. View at: Google Scholar

Copyright © 2013 Markus Donix et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

More related articles

 PDF Download Citation Citation
 Download other formatsMore
 Order printed copiesOrder

Related articles

Article of the Year Award: Outstanding research contributions of 2020, as selected by our Chief Editors. Read the winning articles.